{{Underlinked|date=September 2014}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447910442
| IUPAC_name =  
| image =
<!-- Clinical data -->
| tradename =  
| Drugs.com = {{drugs.com|international|reviparin-sodium}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 9005-49-6
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 5R0L1D739E
| ATC_prefix = B01
| ATC_suffix = AB08
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D03337
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Reviparin''' is an antithrombotic and belongs to the group of [[low molecular weight heparin]]s.

== Pharmacodynamic ==
Reviparin is a low molecular weight heparin ([[LMWH]]) obtained by [[nitrous acid]] depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 [[dalton (unit)|daltons]].

== Indications ==
* [[Thrombosis prevention|Prevention of blood clots]]
* Prophylaxis of perioperative thromboembolism<ref name="pmid8822126">{{cite journal |vauthors=Kakkar VV, Cohen AT, Mohamed MS |title=Patients at risk of venous thromboembolism--clinical results with reviparin |journal=Thromb. Res. |volume=81 |issue=2 Suppl |pages=S39–45 |year=1996 |pmid=8822126 |doi=10.1016/0049-3848(95)00228-6  |url= }}<!--|accessdate=2014-09-18--></ref><ref name="pmid10549720">{{cite journal |vauthors=Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E |title=Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery |journal=Semin. Thromb. Hemost. |volume=25 Suppl 3 |issue= |pages=79–82 |year=1999 |pmid=10549720 |doi= |url= }}<!--|accessdate=2014-09-18--></ref>
* Treatment of DVT with or without pulmonary embolism (PE)<ref name="pmid15887830">{{cite journal |vauthors=Gore M, Kelkar P, Rege N, Ross C |title=Reviparin sodium clivarine: a review of its therapeutic use |journal=J Indian Med Assoc |volume=102 |issue=10 |pages=589–90, 592 | date=October  2004 |pmid=15887830 |doi= |url= }}<!--|accessdate=2014-09-18--></ref>
* Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)<ref name="pmid8180331">{{cite journal |vauthors=Preisack MB, Karsch KR |title=Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty |journal=Blood Coagul. Fibrinolysis |volume=4 Suppl 1 |issue= |pages=S55–8; discussion S59–60 | date=December  1993 |pmid=8180331 |doi= |url= }}<!--|accessdate=2014-09-18--></ref><ref name="pmid8917255">{{cite journal |vauthors=Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R |title=Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation |journal=J. Am. Coll. Cardiol. |volume=28 |issue=6 |pages=1437–43 | date=November  1996 |pmid=8917255 |doi= 10.1016/s0735-1097(96)00343-9|url=http://linkinghub.elsevier.com/retrieve/pii/S0735109796003439 |accessdate=2014-09-18}}</ref>

==References==
{{Reflist}}

==External links==
* {{MeshName|reviparin}}
* {{cite journal  |vauthors=Yusuf S, Mehta SR, Xie C, etal |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427–35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427}}

{{Antithrombotics}}

[[Category:Heparins]]


{{blood-drug-stub}}